Welcome to our dedicated page for ARNA news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on ARNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ARNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ARNA's position in the market.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 17 new employees on June 15, 2021. The options allow for the purchase of 64,401 shares at an exercise price of $65.60, vesting over four years. Additionally, 27,857 RSUs were granted, also vesting over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) to attract new talent. The options and RSUs are part of Arena's 2021 Long-Term Incentive Plan.
Arena Pharmaceuticals (Nasdaq: ARNA) appointed Steven Schoch to its Board of Directors and as Chair of the Audit Committee. Schoch brings over 20 years of financial and operational leadership from biopharmaceuticals and media sectors. Previously, he served as Chief Financial Officer at 23andMe and held executive roles at Miramax and Amgen. Arena's leadership expressed optimism about Schoch's financial and strategic experience benefiting the company's growth plans as they advance a diversified portfolio targeting various therapeutic areas.
Arena Pharmaceuticals (Nasdaq: ARNA) announced that the FDA granted Orphan Drug Designation for etrasimod, a selective sphingosine 1-phosphate receptor modulator, for treating eosinophilic esophagitis (EoE). This drug is currently assessed in the Phase 2b VOYAGE trial, focusing on safety and efficacy in about 100 participants. The designation is significant as no FDA-approved therapies exist for EoE. Arena aims to bring this potential therapy to patients, highlighting its commitment to addressing unmet medical needs.
Arena Pharmaceuticals has initiated a Phase 2 trial for IV temanogrel, targeting coronary microvascular obstruction (cMVO) in patients undergoing percutaneous coronary intervention (PCI). With no FDA-approved treatments for cMVO, this trial aims to evaluate the safety and efficacy of temanogrel. The trial will enroll 99 participants across multiple countries, with a primary endpoint assessing changes in Index of Microcirculatory Resistance. Phase 2 results are anticipated in the latter half of 2022, marking a significant step in Arena's Cardiovascular Portfolio.
Arena Pharmaceuticals (Nasdaq: ARNA) granted inducement stock options to 22 new employees on May 15, 2021. A total of 74,905 shares were authorized for stock options, alongside 32,050 restricted stock units (RSUs). The stock options, with an exercise price of $61.46 per share, vest over four years. The RSUs similarly vest over four years with a structured timeline. Both incentives are governed by Arena's Amended and Restated 2020 Long-Term Incentive Plan, highlighting Arena's commitment to attract talent and support employee retention.
Arena Pharmaceuticals (Nasdaq: ARNA) reported its financial results for Q1 2021, revealing a net loss of $118.4 million, an increase from $100.2 million in Q1 2020. Revenues were nil, down from $0.3 million year-over-year. R&D expenses rose to $102.5 million, driven by clinical advancements, while SG&A expenses increased to $29.5 million. The company highlighted progress in its clinical pipeline, including full enrollment in the ELEVATE UC 52 Phase 3 study for etrasimod and the initiation of additional studies targeting eosinophilic esophagitis and ulcerative colitis.
Arena Pharmaceuticals (Nasdaq: ARNA) will announce its first quarter 2021 financial results and corporate update on May 5, 2021, after U.S. market close. The company will hold a conference call at 4:30 PM ET for investors, providing a platform for questions and discussion. Participants are encouraged to join 20 minutes early for registration. Arena Pharmaceuticals is committed to delivering essential medicines and has emphasized its focus on executing disruptive ideas in the healthcare sector.
Arena Pharmaceuticals (Nasdaq: ARNA) presented additional data from its ADVISE Phase 2b trial for etrasimod, an investigational treatment for moderate-to-severe atopic dermatitis, at the American Academy of Dermatology VMX Experience. The 2 mg dose of etrasimod showed statistically significant improvements in both clinician and patient-reported outcomes. Key results included a 29.8% reduction in the vIGA score and significant enhancements in peak pruritis and overall quality of life measures. Arena plans to advance etrasimod into a Phase 3 program, highlighting its potential as a novel treatment option.
FAQ
What is the market cap of ARNA (ARNA)?
